查看購物車
  • Simplified Chinese
  • English
  • Japanese
多發性骨髓瘤市場:KOL的洞察
市場調查報告書
商品編碼
1749303

多發性骨髓瘤市場:KOL的洞察

KOL Insight - Multiple Myeloma
出版日期: | 出版商: FirstWord Group | 英文 | 商品交期: 最快1-2個工作天內

價格
簡介目錄

從抗CD38和CAR-T細胞療法到雙特異性抗體和抗體藥物偶聯物，本報告探討了多發性骨髓瘤的關鍵進展如何塑造當前和未來的治療途徑。基於對來自美國和歐洲的12位關鍵意見領袖的採訪，我們探討了Darzalex的潛在擴張、BCMA靶向CAR-T細胞療法日益增長的作用，以及吉利德/Arcellx、科濟生物和阿斯特捷利康在研候選藥物的前景。隨著臨床醫師對療效和安全性的不斷改進，我們也關注了Tekbairi和Ellexfio等雙特異性抗體以及葛蘭素史克的Brenrep的再次崛起。深入了解未來3-5年骨髓瘤治療的發展方向。

關鍵問題

  • 1.未來3-5年，骨髓瘤治療領域最大的改變因素是什麼？
  • 2.Darzalex 能否在高風險冒煙型骨髓瘤的治療中扮演重要角色？
  • 3.Darzalex 在新診斷和復發患者中的定位如何演變？
  • 4.Sarclisa 能否與 Darzalex 競爭？
  • 5.KOL 如何看待伊比多胺和美齊多胺與先前的免疫療法藥物 (IMiD) 相比？
  • 6.CAR-T 細胞療法在不久的將來將如何發展？
  • 7.靶向 BCMA 的雙特異性抗體在早期治療中的前景如何？
  • 8.鑑於對眼睛毒性的擔憂，Brenerep 重返市場是否值得歡迎？

領導品牌

  • Darzalex（達雷妥尤單抗）
  • Sarclisa（伊沙妥昔單抗）
  • Calvicty（siltacabtagene autoleucel）
  • Avekuma（艾德卡布他單抗）
  • Tekbairi（泰克利司他單抗）
  • Ellexfio（厄拉那單抗）
  • Talbay（塔爾奎單抗）
  • Brenrep（貝蘭他單抗）馬福多汀)
  • 伊貝多胺
  • 美齊格多胺
  • 阿尼託卡比單抗 (CART-ddBCMA)
  • 澤伏他定單抗 (CT 053)
  • AZD0120
  • 阿洛卡比單抗 (Allocabtadine)
  • 利諾西汀 (Rinozyfic) (瑞博舍他單抗)
  • 依替米格
  • 西沃他單抗

調查手法

"治療趨勢" 報告透過對全球領先的關鍵意見領袖 (KOL) 進行深入訪談，就關鍵疾病領域的當前和未來治療前景進行深入分析。 KOL 的篩選標準非常嚴格，包括全球聲譽、臨床專業知識以及在治療領域的影響力。每次訪談都配有精心設計的討論指南。這些指南由我們與關鍵意見領袖 (KOL) 合作開發，並由行業專家進行同行評審，以確保所提問題全面且與當前市場動態相關。每份報告發布後，我們都會持續進行12個月的市場監測，及時提供關鍵意見領袖 (KOL) 對重要新聞事件、市場變化和市場發展的更新。

我們的報告有何特別之處？

FirstWord Reports 是值得信賴的行業領導者，專注於製藥業，為生物製藥專業人士和決策者提供深入、可操作的洞察。我們深厚的行業知識使我們能夠為您提供相關且有價值的洞察，幫助您掌握新興趨勢並有效應對複雜課題。憑藉廣泛的研究以及來自頂尖專家和關鍵意見領袖的獨立、公正的見解，我們的報告為您提供所需的準確性和可靠性。獨家存取獨家訪談和數據，以及持續的市場監測，讓您全面了解市場動態。我們的報告涵蓋40多個動態疾病領域、包括 KOL 洞察和定量醫生調查在內的醫生情報，以及行業專家對醫療事務、數位健康、銷售和營銷、市場准入和其他領域問題的看法，使您能夠做出更明智的數據驅動決策，並在快速變化的行業中保持競爭力。

簡介目錄

This report examines how key developments in multiple myeloma-ranging from anti-CD38 therapies and CAR T-cell treatments to bispecific antibodies and antibody-drug conjugates-are shaping current and future treatment pathways. Based on interviews with 12 KOLs in the US and Europe, it explores the potential expansion of Darzalex, the growing role of BCMA-targeting CAR T-cell therapies, and the outlook for pipeline candidates from Gilead/Arcellx, CARsgen, and AstraZeneca. It also considers the positioning of bispecific antibodies such as Tecvayli and Elrexfio, and the re-emergence of GSK's Blenrep, as clinicians weigh up evolving efficacy and safety profiles. Gain a clearer view of how the myeloma treatment landscape is expected to evolve over the next 3-5 years.

Key Questions Answered:

  • 1. What are the biggest drivers of change in myeloma treatment over the next 3-5 years?
  • 2. Could Darzalex play a meaningful role in treating high-risk smouldering myeloma?
  • 3. How is Darzalex's position evolving across newly diagnosed and relapsed settings?
  • 4. Can Sarclisa compete with Darzalex, and will a subcutaneous option boost its uptake?
  • 5. How do KOLs view iberdomide and mezigdomide compared to older IMiDs?
  • 6. How will the use of CAR T-cell therapies shift in the near term?
  • 7. What is the outlook for BCMA-directed bispecific antibodies in earlier lines of therapy?
  • 8. Will Blenrep's re-entry into the market be welcomed despite ocular toxicity concerns?

Key Brands:

  • Darzalex (daratumumab)
  • Sarclisa (isatuximab)
  • Carvykti (ciltacabtagene autoleucel)
  • Abecma (idecabtagene vicleucel)
  • Tecvayli (teclistamab)
  • Elrexfio (elranatamab)
  • Talvey (talquetamab)
  • Blenrep (belantamab mafodotin)
  • iberdomide
  • mezigdomide
  • anitocabtagene autoleucel (CART-ddBCMA)
  • zevorcabtagene autoleucel (CT 053)
  • AZD0120
  • arlocabtagene autoleucel
  • Lynozyfic (linvoseltamab)
  • etentamig
  • cevostamab

Methodology:

Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.